Putting More Weight on Obesity Trials in Heart Failure

Josephine Harrington; Naveed Sattar; G. Michael Felker; James L. Januzzi; Carolyn S.P. Lam; Neha J. Pagidipati; Ambarish Pandey; Harriette G.C. Van Spall; Darren K. McGuire

doi:10.1007/s11897-024-00655-z

Putting More Weight on Obesity Trials in Heart Failure

Josephine Harrington, Naveed Sattar, G. Michael Felker, James L. Januzzi, Carolyn S.P. Lam, Neha J. Pagidipati, Ambarish Pandey, Harriette G.C. Van Spall, Darren K. McGuire

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Purpose of Review: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. Recent Findings: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Summary: Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.

Original language	English (US)
Pages (from-to)	194-202
Number of pages	9
Journal	Current heart failure reports
Volume	21
Issue number	3
DOIs	https://doi.org/10.1007/s11897-024-00655-z
State	Published - Jun 2024

Keywords

Clinical trial
Heart failure
Obesity
Weight loss

ASJC Scopus subject areas

Emergency Medicine
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s11897-024-00655-z

Cite this

@article{cb1ac3e174d043b197908c7e17cb98a8,

title = "Putting More Weight on Obesity Trials in Heart Failure",

abstract = "Purpose of Review: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. Recent Findings: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Summary: Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.",

keywords = "Clinical trial, Heart failure, Obesity, Weight loss",

author = "Josephine Harrington and Naveed Sattar and Felker, {G. Michael} and Januzzi, {James L.} and Lam, {Carolyn S.P.} and Pagidipati, {Neha J.} and Ambarish Pandey and {Van Spall}, {Harriette G.C.} and McGuire, {Darren K.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.",

year = "2024",

month = jun,

doi = "10.1007/s11897-024-00655-z",

language = "English (US)",

volume = "21",

pages = "194--202",

journal = "Current heart failure reports",

issn = "1546-9530",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Putting More Weight on Obesity Trials in Heart Failure

AU - Harrington, Josephine

AU - Sattar, Naveed

AU - Felker, G. Michael

AU - Januzzi, James L.

AU - Lam, Carolyn S.P.

AU - Pagidipati, Neha J.

AU - Pandey, Ambarish

AU - Van Spall, Harriette G.C.

AU - McGuire, Darren K.

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.

PY - 2024/6

Y1 - 2024/6

N2 - Purpose of Review: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. Recent Findings: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Summary: Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.

AB - Purpose of Review: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. Recent Findings: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Summary: Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.

KW - Clinical trial

KW - Heart failure

KW - Obesity

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=85190465580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85190465580&partnerID=8YFLogxK

U2 - 10.1007/s11897-024-00655-z

DO - 10.1007/s11897-024-00655-z

M3 - Review article

C2 - 38619690

AN - SCOPUS:85190465580

SN - 1546-9530

VL - 21

SP - 194

EP - 202

JO - Current heart failure reports

JF - Current heart failure reports

IS - 3

ER -

Putting More Weight on Obesity Trials in Heart Failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this